Christopher Kratochvil

Summary

Affiliation: University of Nebraska Medical Center
Country: USA

Publications

  1. doi request reprint Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy
    Diane E May
    Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska 68198 5581, USA
    Drugs 70:15-40. 2010
  2. ncbi request reprint An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder
    C J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, Omaha 68191 5581, USA
    J Child Adolesc Psychopharmacol 11:167-70. 2001
  3. ncbi request reprint Review of pediatric attention deficit/hyperactivity disorder for the general psychiatrist
    Christopher J Kratochvil
    Department of Psychiatry, Division of Child and Adolescent Psychiatry, University of Nebraska Medical Center, 985581 Nebraska Medical Center, Omaha, NE 68198 5581, USA
    Psychiatr Clin North Am 32:39-56. 2009
  4. ncbi request reprint Pharmacological management of agitation and aggression in an adolescent with autism
    Christopher J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, Omaha, NE 68198, USA
    J Am Acad Child Adolesc Psychiatry 44:829-32. 2005
  5. ncbi request reprint Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms
    Christopher J Kratochvil
    Department of Psychiatry, Nebraska Medical Center, Omaha 68198 5581, USA
    J Am Acad Child Adolesc Psychiatry 44:915-24. 2005
  6. ncbi request reprint Pharmacological management of new-onset bipolar disorder
    Christopher J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, Omaha, NE 68198 5581, USA
    J Am Acad Child Adolesc Psychiatry 44:1198-200. 2005
  7. ncbi request reprint Emotional expression during attention-deficit/hyperactivity disorders treatment: initial assessment of treatment effects
    C J Kratochvil
    University of Nebraska Medical Center, Omaha, Nebraska, USA
    J Child Adolesc Psychopharmacol 17:51-62. 2007
  8. ncbi request reprint Pharmacological management of preschool ADHD
    Christopher J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, Omaha 68198 5581, and the Department of Psychiatry, New York State Psychiatric Institute, New York, USA
    J Am Acad Child Adolesc Psychiatry 45:115-8. 2006
  9. pmc A double-blind, placebo-controlled study of atomoxetine in young children with ADHD
    Christopher J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, 985581 Nebraska Medical Center, Omaha, NE 68198 5581, USA
    Pediatrics 127:e862-8. 2011
  10. ncbi request reprint Acute time to response in the Treatment for Adolescents with Depression Study (TADS)
    Christopher Kratochvil
    University of Nebraska Medical Center NE 68198 5581, USA
    J Am Acad Child Adolesc Psychiatry 45:1412-8. 2006

Research Grants

  1. Pharmacological Treatment of ADHD in Young Children
    Christopher Kratochvil; Fiscal Year: 2007

Detail Information

Publications68

  1. doi request reprint Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy
    Diane E May
    Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska 68198 5581, USA
    Drugs 70:15-40. 2010
    ..Such recent developments and ongoing study of additional potential pharmacological interventions may lead to additional future treatment options for children with ADHD...
  2. ncbi request reprint An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder
    C J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, Omaha 68191 5581, USA
    J Child Adolesc Psychopharmacol 11:167-70. 2001
    ..To collect pilot data assessing the safety, tolerability, and efficacy of tomoxetine, a nonstimulant norepinephrine enhancer, in pediatric attention deficit hyperactivity disorder (ADHD)...
  3. ncbi request reprint Review of pediatric attention deficit/hyperactivity disorder for the general psychiatrist
    Christopher J Kratochvil
    Department of Psychiatry, Division of Child and Adolescent Psychiatry, University of Nebraska Medical Center, 985581 Nebraska Medical Center, Omaha, NE 68198 5581, USA
    Psychiatr Clin North Am 32:39-56. 2009
    ..Background information, recent relevant research, current evidence-based practice guidelines, and tips for clinical practice are reviewed in this article. The information is presented in a question-answer format...
  4. ncbi request reprint Pharmacological management of agitation and aggression in an adolescent with autism
    Christopher J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, Omaha, NE 68198, USA
    J Am Acad Child Adolesc Psychiatry 44:829-32. 2005
  5. ncbi request reprint Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms
    Christopher J Kratochvil
    Department of Psychiatry, Nebraska Medical Center, Omaha 68198 5581, USA
    J Am Acad Child Adolesc Psychiatry 44:915-24. 2005
    ..The authors assessed the safety and effectiveness of atomoxetine monotherapy compared with combined atomoxetine/fluoxetine therapy in a population of children and adolescents with ADHD and concurrent symptoms of depression or anxiety...
  6. ncbi request reprint Pharmacological management of new-onset bipolar disorder
    Christopher J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, Omaha, NE 68198 5581, USA
    J Am Acad Child Adolesc Psychiatry 44:1198-200. 2005
  7. ncbi request reprint Emotional expression during attention-deficit/hyperactivity disorders treatment: initial assessment of treatment effects
    C J Kratochvil
    University of Nebraska Medical Center, Omaha, Nebraska, USA
    J Child Adolesc Psychopharmacol 17:51-62. 2007
    ....
  8. ncbi request reprint Pharmacological management of preschool ADHD
    Christopher J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, Omaha 68198 5581, and the Department of Psychiatry, New York State Psychiatric Institute, New York, USA
    J Am Acad Child Adolesc Psychiatry 45:115-8. 2006
  9. pmc A double-blind, placebo-controlled study of atomoxetine in young children with ADHD
    Christopher J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, 985581 Nebraska Medical Center, Omaha, NE 68198 5581, USA
    Pediatrics 127:e862-8. 2011
    ..To evaluate the efficacy and tolerability of atomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in 5- and 6-year-old children...
  10. ncbi request reprint Acute time to response in the Treatment for Adolescents with Depression Study (TADS)
    Christopher Kratochvil
    University of Nebraska Medical Center NE 68198 5581, USA
    J Am Acad Child Adolesc Psychiatry 45:1412-8. 2006
    ..To examine the time to response for both pharmacotherapy and psychotherapy in the Treatment for Adolescents with Depression Study (TADS)...
  11. ncbi request reprint Selective serotonin reuptake inhibitors in pediatric depression: is the balance between benefits and risks favorable?
    Christopher J Kratochvil
    University of Nebraska Medical Center, Omaha, Nebraska 68198, USA
    J Child Adolesc Psychopharmacol 16:11-24. 2006
    ..The authors have concluded that SSRIs -- in particular, fluoxetine -- do have a role in the treatment of pediatric depression...
  12. ncbi request reprint Less is more: inpatient management of a child with complex pharmacotherapy
    Christopher J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, Omaha, 68198, USA
    J Am Acad Child Adolesc Psychiatry 45:621-4. 2006
  13. ncbi request reprint Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder
    Christopher J Kratochvil
    University of Nebraska Medical Center, Omaha, NE 68198 5581, USA
    J Am Acad Child Adolesc Psychiatry 45:919-27. 2006
    ....
  14. ncbi request reprint Pharmacological management of a teen with significant alcohol use and depression
    Christopher J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, Omaha, NE 68198 5581, USA
    J Am Acad Child Adolesc Psychiatry 45:1011-5. 2006
  15. ncbi request reprint Atomoxetine in the treatment of attention deficit hyperactivity disorder
    Christopher J Kratochvil
    University of Nebraska Medical Center, Omaha, NE 68198 5581, USA
    Expert Rev Neurother 4:601-11. 2004
    ..This article reviews the available information on atomoxetine, accompanied by a discussion of its clinical use...
  16. ncbi request reprint Pharmacological management of treatment-induced insomnia in ADHD
    Christopher J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, Omaha, NE 68195 5581, USA
    J Am Acad Child Adolesc Psychiatry 44:499-501. 2005
  17. ncbi request reprint Pharmacotherapy of childhood anxiety disorders
    Christopher J Kratochvil
    Department of Child and Adolescent Psychiatry, University of Nebraska Medical Center, 44th and Emile, Omaha, NE 68198, USA
    Curr Psychiatry Rep 4:264-9. 2002
    ..This article will review significant pharmacologic studies published in the prior year, and the role of pharmacotherapy in the treatment of pediatric anxiety disorders...
  18. ncbi request reprint High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses
    Christopher J Kratochvil
    University of Nebraska Medical Center, Omaha, NE 68198, USA
    J Am Acad Child Adolesc Psychiatry 46:1128-37. 2007
    ..To assess the utility and tolerability of higher than standard atomoxetine doses to treat attention-deficit/hyperactivity disorder (ADHD)...
  19. ncbi request reprint Selecting an antidepressant for the treatment of pediatric depression
    Christopher J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, Omaha 68198 5581, USA
    J Am Acad Child Adolesc Psychiatry 45:371-3. 2006
  20. ncbi request reprint Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder
    Christopher J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, Omaha 68191 5581, USA
    Expert Opin Pharmacother 4:1165-74. 2003
    ..Atomoxetine is the first nonstimulant approved by the FDA for the treatment of ADHD and the first medication approved for the treatment of adult ADHD...
  21. ncbi request reprint A pilot study of atomoxetine in young children with attention-deficit/hyperactivity disorder
    Christopher J Kratochvil
    University of Nebraska Medical Center, Omaha, Nebraska, USA
    J Child Adolesc Psychopharmacol 17:175-85. 2007
    ..The purpose of this study was to assess the effectiveness and tolerability of atomoxetine during acute treatment of attention-deficit/hyperactivity disorder (ADHD) in 5 and 6 year olds...
  22. pmc Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study
    Christopher J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska, USA
    J Child Adolesc Psychopharmacol 19:519-27. 2009
    ..Because attention-deficit/hyperactivity disorder (ADHD) and major depressive disorder (MDD) frequently co-exist, we examined whether ADHD moderated these outcomes in TADS...
  23. ncbi request reprint Pharmacological management of treatment-resistant pediatric depression
    Christopher J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, Omaha, NE 68195 5581, USA
    J Am Acad Child Adolesc Psychiatry 44:198-200. 2005
  24. ncbi request reprint Pharmacological management of a youth with ADHD, marijuana use, and mood symptoms
    Christopher J Kratochvil
    Department of Psychiatry, University of Nebraska Medical Center, Omaha 68198 5581, USA
    J Am Acad Child Adolesc Psychiatry 45:1138-41. 2006
  25. doi request reprint Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder
    Jeffrey H Newcorn
    Mount Sinai School of Medicine, New York, NY 10029, USA
    J Am Acad Child Adolesc Psychiatry 48:1165-72. 2009
    ....
  26. doi request reprint Beyond the 'typical' patient: treating attention-deficit/hyperactivity disorder in preschoolers and adults
    Brigette S Vaughan
    Department of Psychiatry, University of Nebraska Medical Center, Omaha, NE 68198 5581, USA
    Int Rev Psychiatry 20:143-9. 2008
    ..More research, however, is needed to determine the safest and most effective pharmacotherapies and psychosocial interventions for these non-typical patients...
  27. doi request reprint Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response
    Jeffrey H Newcorn
    Department of Psychiatry, Mount Sinai Medical Center, Box 1230, One Gustave L Levy Place, New York, NY 10029, USA
    Am J Psychiatry 165:721-30. 2008
    ....
  28. ncbi request reprint Innovations and recent trends in the treatment of ADHD
    Vishal Madaan
    Child and Adolescent Psychiatry, Creighton University University of Nebraska Medical Center, Omaha, NE, USA
    Expert Rev Neurother 6:1375-85. 2006
    ..This review highlights some of the recent trends in ADHD treatment and the current status of promising treatment options that may help to shape the future of ADHD treatment...
  29. ncbi request reprint Factors associated with recruitment and screening in the Treatment for Adolescents With Depression Study (TADS)
    Diane E May
    University of Nebraska Medical Center, Omaha, NE 68198 5581, USA
    J Am Acad Child Adolesc Psychiatry 46:801-10. 2007
    ..To examine factors associated with eligibility and randomization and consider the efficiency of recruitment methods...
  30. doi request reprint Attention deficit hyperactivity disorder in preschool children
    Laurence L Greenhill
    Department of Psychiatry, New York State Psychiatric Institute, Unit 78, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA
    Child Adolesc Psychiatr Clin N Am 17:347-66, ix. 2008
    ..Newly available data on the safety and efficacy of pharmacotherapy and psychosocial intervention for preschoolers who have ADHD may help clinicians make treatment decisions for these young children and their families...
  31. ncbi request reprint A manual-based intervention to address clinical crises and retain patients in the Treatment of Adolescents With Depression Study (TADS)
    Diane E May
    University of Nebraska Medical Center, Omaha, NE 68198 5581, USA
    J Am Acad Child Adolesc Psychiatry 46:573-81. 2007
    ..To describe a manual-based intervention to address clinical crises and retain participants in the Treatment for Adolescents With Depression Study (TADS)...
  32. ncbi request reprint Diagnosis and treatment of adult attention-deficit/hyperactivity disorder at US ambulatory care visits from 1996 to 2003
    Jayashri Sankaranarayanan
    Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center, 986045 Nebraska Medical Center, Omaha, NE 68198, USA
    Curr Med Res Opin 22:1475-91. 2006
    ....
  33. ncbi request reprint Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial
    Christopher J Kratochvil
    University of Nebraska Medical Center, USA
    J Am Acad Child Adolesc Psychiatry 41:776-84. 2002
    ..Atomoxetine was originally called tomoxetine. The name was recently changed in order to avoid any potential confusion with tamoxifen that might lead to errors in dispensing drug.)..
  34. ncbi request reprint The assessment of attention-deficit/hyperactivity disorder in rural primary care: the portability of the American Academy of Pediatrics guidelines to the "real world"
    Jodi Polaha
    Department of Psychology, Munroe Meyer Institute, University of Nebraska, 985450 Nebraska Medical Center, Omaha, NE 68105, USA
    Pediatrics 115:e120-6. 2005
    ..The protocol was designed to provide an efficient means for pediatricians to learn and use the ADHD guidelines put forth by the American Academy of Pediatrics (AAP)...
  35. ncbi request reprint The role of stimulants in the treatment of preschool children with attention-deficit hyperactivity disorder
    Christopher J Kratochvil
    University of Nebraska Medical Center, Omaha, Nebraska 68198 5581, USA
    CNS Drugs 18:957-66. 2004
    ....
  36. ncbi request reprint Pharmacotherapy of aggression in a 9-year-old with ADHD
    Robert L Findling
    Department of Psychiatry, University Hospital of Cleveland Case Western Reserve University, Cleveland, Ohio 44106, USA
    J Am Acad Child Adolesc Psychiatry 46:653-8. 2007
  37. ncbi request reprint Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder
    Jeffrey H Newcorn
    Mount Sinai Medical Center, Department of Psychiatry, One Gustave L Levy Place, Box 1230, New York, NY 10029, USA
    Pediatrics 118:e1701-6. 2006
    ..However, lower doses could be effective during maintenance treatment, which would reduce drug exposure and potential problems related to tolerability during chronic treatment...
  38. ncbi request reprint Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Massachusetts General Hospital, Department of Psychiatry, Boston, Massachusetts, USA
    J Pediatr 149:112-9. 2006
    ..To determine the efficacy and safety of atomoxetine in adolescent subjects treated for attention-deficit/hyperactivity disorder (ADHD) for up to 2 years...
  39. ncbi request reprint Developing strategies for psychopharmacological studies in preschool children
    Laurence L Greenhill
    New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY 10032, USA
    J Am Acad Child Adolesc Psychiatry 42:406-14. 2003
    ..To identify the obstacles and special challenges-ethical, practical, scientific, and regulatory-faced by investigators who attempt to conduct psychopharmacological studies in preschoolers...
  40. ncbi request reprint Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder
    Brigette Vaughan
    Nebraska Medical Center, Department of Psychiatry, Omaha, NE 68198, USA
    Expert Opin Pharmacother 10:669-76. 2009
    ..Since that time, the use of atomoxetine has spread globally and extensive additional research has been conducted evaluating its efficacy and safety...
  41. ncbi request reprint Antidepressant management in the context of suicidal ideation
    Graham J Emslie
    Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, TX, USA
    J Am Acad Child Adolesc Psychiatry 46:1222-5. 2007
  42. pmc Dysfunctional attitudes scale perfectionism: a predictor and partial mediator of acute treatment outcome among clinically depressed adolescents
    RACHEL H JACOBS
    Department of Psychiatry, Northwestern University Feinberg School of Medicine, USA
    J Clin Child Adolesc Psychol 38:803-13. 2009
    ..In the case of suicidality, DAS perfectionism impeded improvement. Treatment outcomes were partially mediated by the change in DAS perfectionism across the 12-week period...
  43. ncbi request reprint Is there a role for clozapine in the treatment of children and adolescents?
    Robert L Findling
    Department of Psychiatry, University Hospitals of Cleveland Case Western Reserve University, USA
    J Am Acad Child Adolesc Psychiatry 46:423-8. 2007
  44. ncbi request reprint Assessing the efficacy of treatments for ADHD : overview of methodological issues
    Vishal Madaan
    Creighton University University of Nebraska Medical Center, Omaha, Nebraska, USA
    CNS Drugs 22:275-90. 2008
    ....
  45. doi request reprint Antidepressant prescribing practices for the treatment of children and adolescents
    Supriya K Bhatia
    Psychopharmacology Research Center, 985581 University of Nebraska Medical Center, Omaha, NE 68198, USA
    J Child Adolesc Psychopharmacol 18:70-80. 2008
    ..This study evaluates pediatric antidepressant prescribing practices of Nebraska clinicians...
  46. ncbi request reprint Diagnosing and managing complicated ADHD
    Robert L Findling
    Department of Psychiatry and Pediatrics, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio, USA
    J Clin Psychiatry 68:1963-70. 2007
  47. pmc Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy
    Paul Rohde
    Oregon Research Institute, 1715 Franklin Blvd, Eugene, OR 97403 1983, USA
    Arch Gen Psychiatry 65:447-55. 2008
    ..Treatment consisted of 3 stages: (1) acute (12 weeks), (2) continuation (6 weeks), and (3) maintenance (18 weeks)...
  48. doi request reprint Emotional expression in children treated with ADHD medication: development of a new measure
    Amy R Perwien
    Eli Lilly and Company
    J Atten Disord 11:568-79. 2008
    ....
  49. ncbi request reprint Research knowledge among the participants in the Treatment for Adolescents With Depression Study (TADS)
    Benedetto Vitiello
    Division of Services and Intervention Research, National Institute of Mental Health, Bethesda, MD 20892 9633, USA
    J Am Acad Child Adolesc Psychiatry 46:1642-50. 2007
    ..We examined the extent to which parents and adolescents participating in the Treatment for Adolescents With Depression Study (TADS) understood key aspects of the study...
  50. ncbi request reprint Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder
    Joseph Biederman
    Massachusetts General Hospital, Boston, Massachusetts, USA
    Pediatrics 110:e75. 2002
    ..Atomoxetine is a potent inhibitor of the presynaptic norepinephrine transporter with minimal affinity for other noradrenergic receptors or for other neurotransmitter transporters or receptors...
  51. ncbi request reprint Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the treatment for adolescents with depression study
    Sanjeev Pathak
    University of Cincinnati College of Medicine, Children s Hospital Medical Center, MLC D 3014, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
    Curr Psychiatry Rep 7:429-34. 2005
    ..Moreover, the study results confirm that fluoxetine alone is effective in the treatment of depressed adolescents...
  52. ncbi request reprint Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study
    Joseph Biederman
    Department of Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114, USA
    Pediatrics 116:e777-84. 2005
    ..This study evaluated a new formulation of modafinil (modafinil film-coated tablets) in children and adolescents with ADHD...
  53. ncbi request reprint The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder
    Louis S Matza
    MEDTAP International, Inc, Bethesda, Maryland, USA
    J Dev Behav Pediatr 25:166-74. 2004
    ..The findings suggest that HRQL instruments can add important information to efficacy measures in clinical trials of ADHD treatment...
  54. ncbi request reprint Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder
    Timothy E Wilens
    Pediatric Psychopharmacology Unit, Massachusetts General Hospital, YAW 6 6A, 32 Fruit Street, Boston, MA 02114, USA
    Arch Pediatr Adolesc Med 160:82-90. 2006
    ..Despite the persistence of attention-deficit/hyperactivity disorder (ADHD) into adolescence, little is known about the efficacy and tolerability of stimulant medications in this age group...
  55. ncbi request reprint Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning
    Ronald T Brown
    Temple University, Department of Public Health, PA 19140, USA
    Clin Pediatr (Phila) 45:819-27. 2006
    ..The effects of atomoxetine on other functional outcomes including academic performance and health-related outcomes are of interest, albeit less compelling for this particular investigation, than for the effects on overt symptom display...
  56. doi request reprint Cost-effectiveness of treatments for adolescent depression: results from TADS
    Marisa Elena Domino
    Department of Health Policy and Administration, School of Public Health, University of North Carolina at Chapel Hill, 1104G McGavran Greenberg Hall, CB 7411, Chapel Hill, NC 27599, USA
    Am J Psychiatry 165:588-96. 2008
    ..Treatment costs are a relevant concern given the competing demands on family and health care budgets. The authors evaluated the cost-effectiveness of three active treatments among adolescents with major depressive disorder...
  57. ncbi request reprint Pharmacological management of a youth with ADHD and a seizure disorder
    Joseph Gonzalez-Heydrich
    Children s Hospital Boston and Harvard Medical School, USA
    J Am Acad Child Adolesc Psychiatry 45:1527-32. 2006
  58. ncbi request reprint Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes?
    Amy R Perwien
    Outcomes Research, US Medical Division, Eli Lilly and Company, Indianapolis, Indiana, USA
    J Child Adolesc Psychopharmacol 16:713-24. 2006
    ..This study examines the long-term effects of pharmacological treatment with atomoxetine on HRQL in children and adolescents with ADHD...
  59. ncbi request reprint Safety profile of atomoxetine in the treatment of children and adolescents with ADHD
    J F Wernicke
    Eli Lilly and Company, Lilly Corporate Center DC 6026, Indianapolis, IN 46285, USA
    J Clin Psychiatry 63:50-5. 2002
    ..Specifically, cardiac effects and effects on weight, height, and metabolism that are related to treatment of ADHD with atomoxetine in children and adolescents are discussed...
  60. ncbi request reprint Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder
    Thomas Spencer
    Massachusetts General Hospital, Boston, USA
    J Clin Psychiatry 63:1140-7. 2002
    ..Results of 2 proof-of-concept studies are reported that tested the hypothesis that a selective inhibitor of presynaptic norepinephrine uptake would be effective for the treatment of ADHD in school-aged children...
  61. ncbi request reprint Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment
    Thomas J Spencer
    Massachusetts General Hospital Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    J Child Adolesc Psychopharmacol 17:689-700. 2007
    ..To examine the effects on growth of long-term pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), we present findings from an ongoing 5-year study of the efficacy and safety of treatment with atomoxetine...
  62. ncbi request reprint Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine
    Amy R Perwien
    Outcomes Research, US Medical Division, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Dev Behav Pediatr 25:264-71. 2004
    ..Findings demonstrate the positive impact of atomoxetine on HRQL in children with ADHD...
  63. ncbi request reprint Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder
    Thomas J Spencer
    Massachusetts General Hospital, Boston, MA 02114, USA
    Pediatrics 116:e74-80. 2005
    ..This meta-analysis examined the effect on growth of atomoxetine, now approved in the United States for the treatment of attention-deficit/hyperactivity disorder...
  64. pmc Joint analysis of the DRD5 marker concludes association with attention-deficit/hyperactivity disorder confined to the predominantly inattentive and combined subtypes
    Naomi Lowe
    Department of Genetics, Trinity College, Dublin 2, Ireland
    Am J Hum Genet 74:348-56. 2004
    ..The joint analysis showed association with the DRD5 locus (P=.00005; odds ratio 1.24; 95% confidence interval 1.12-1.38). This association appears to be confined to the predominantly inattentive and combined clinical subtypes...
  65. ncbi request reprint Pharmacological management of bipolar disorder in a youth with diabetes
    Melissa P DelBello
    University of Cincinnati College of Medicine, USA
    J Am Acad Child Adolesc Psychiatry 46:1375-9. 2007
  66. ncbi request reprint Pharmacotherapy for anxiety disorders in children and adolescents: an evidence-based medicine review
    Scott N Compton
    Pediatric Psychiatry, Duke University Medical Center, DUMC Box 3527, Durham, NC 27710, USA
    Pediatr Ann 36:586-90, 592, 594-8. 2007
  67. ncbi request reprint Ethics and the prescription pad
    Mary Lynn Dell
    Psychiatry and Behavioral Sciences, Emory University School of Medicine, 492 Ponce de Leon Manor NE, Atlanta, GA 30307, USA
    Child Adolesc Psychiatr Clin N Am 17:93-111, ix. 2008
    ..Ramifications of black box warnings and off label prescribing are discussed. Finally, the authors offer practical tips to guide clinicians in ethical psychopharmacologic management of their child and adolescent patients...

Research Grants1

  1. Pharmacological Treatment of ADHD in Young Children
    Christopher Kratochvil; Fiscal Year: 2007
    ..b>Christopher Kratochvil with the training and mentorship necessary to establish himself as an independent clinical researcher in ..